RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Prospective validation of single mouse testing (SMT) by the pediatric preclinical testing consortium (PPTC)
Houghton, P. J., Kurmasheva, R. T., Erickson, S., Smith, M. A., Lock, R. B., Evans, K., & Toscan, C. (2020). Prospective validation of single mouse testing (SMT) by the pediatric preclinical testing consortium (PPTC). European Journal of Cancer, 138(SUPPLEMENT 2), S18. https://doi.org/10.1016/s0959-8049(20)31111-4
Background: The Research to Accelerate Cures and Equity for Children Act (RACE for Children Act) requires the FDA to develop a list of molecular targets of new drugs and biologics in development that are determined to be substantially relevant to the growth and progression of pediatric cancer, and that may trigger the requirement for pediatric investigations. This will require approaches to preclinical testing that incorporate models that accurately represent the genetic/epigenetic heterogeneity of pediatric cancers.
SATURDAY, 24 OCTOBER 2020 22:00–22:50: POSTER DISCUSSION SESSION: CANCER THERAPEUTICS: PRECLINICAL MODELING AND PATIENT STRATIFICATION